Skip to main content
Prepare for an exciting September! Each week, we'll examine the latest trends in PAT, offering fresh insights straight from recent conferences. Your perspective matters, so we encourage you to share your thoughts as well. Stay informed, stay engaged, and let's explore these cutting-edge developments together. https://bit.ly/3Xw0X7k
18.118.12.34

Why We Need Continuous Pharmaceutical Manufacturing and How to Make It Happen

By Clive Badman; Charles L.Cooney; Alastair Florence; Konstantin Konstantinov; Markus Krumme; Salvatore Mascia; Moheb Nasr; Bernhardt L. Trout

View Resource (DOI)

Category

Peer-reviewed journal

Published on CMKC

Abstract

We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.

Journal

Journal of Pharmaceutical Sciences. Volume 11, 2019, 3521-3523

DOI

10.1016/j.xphs.2019.07.016

Type of publication

Peer-reviewed journal

Affiliations

  • Massachusetts Institute of Technology (MIT) (MIT)
  • University of Strathclyde
  • University of Strathclyde, Massachusetts Institute of Technology (MIT) (MIT), Codiak BioSciences, Novartis Pharma AG, CONTINUUS, Nasr Pharma Regulatory Consulting

Article Classification

Research article

Classification Areas

  • Regulatory
  • Process Control

Tags

  1. Advanced manufacturing
  2. continuous manufacturing
  3. Model-based control
  4. Personalized medicine
  5. process control
  6. regulatory
  7. regulatory incentives
  8. Research Article
  9. tax incentives